Loading company…
ZymoGenetics, Inc. is a Seattle biopharmaceutical company developing therapies for serious diseases such as cancer.
Founded in 1981 in Seattle, US, ZymoGenetics, Inc. develops and commercializes biopharmaceutical products for serious diseases, particularly cancer and cardiovascular conditions. Bristol-Myers Squibb acquired the company in 2010 for USD 885 mn, with the most recent deal on September 8, 2010. In 2009 the company reported revenue of USD 136.97 mn and EBITDA of USD -23.58 mn, mainly from direct sales and negotiated agreements with healthcare providers.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in